Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xylometazoline + sodium hyaluronate nasal spray for acute viral rhinosinusitis
2022-002499-35Phase 3Completed
- Sponsor
- JGL Group
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xylometazoline and sodium hyaluronate in viral rhinitis (4 arms), sponsored by JGL Group. Primary endpoint: Adjusted mean AUC of Total Nasal Symptom Score after baseline. Started Aug 2022; status: completed.
02
Drugs
xylometazolinesodium hyaluronate
03
Conditions
viral rhinitis
Beyond the preview
Go deeper on 2022-002499-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002499-35.